CIBC Private Wealth Group
NKTR icon

CIBC Private Wealth Group’s Nektar Therapeutics NKTR Stock Holding History

CIBC Private Wealth Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$4.23K Hold
100
– – ﹤0.01% 2660
2025
Q3 		$5.69K Buy
+100
New +$3.31K ﹤0.01% 2531
2018
Q2 		– Sell
-764
Closed -$1.22M – 2047
2018
Q1 		$1.22M Buy
+764
New +$984K 0.01% 607

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CIBC Private Wealth Group's NKTR Position: Q4 2025 in Review

CIBC Private Wealth Group held its Nektar Therapeutics (NKTR) position steady in Q4 2025 at 100 shares worth $4.23K. The position accounts for ﹤0.01% of the portfolio, ranked #2660.

CIBC Private Wealth Group first reported a position in NKTR in Q1 2018 and has held it in 3 quarters since. The position peaked at $1.22M in Q1 2018. 180 funds tracked by Wall St. Rank hold NKTR as of Q4 2025.

  • CIBC Private Wealth Group held 100 shares of Nektar Therapeutics worth $4.23K as of Q4 2025.
  • CIBC Private Wealth Group left its Nektar Therapeutics share count unchanged in Q4 2025.
  • Nektar Therapeutics made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #2660 holding.
  • CIBC Private Wealth Group first reported a position in Nektar Therapeutics in Q1 2018 and has held it in 3 quarters since.
  • CIBC Private Wealth Group's Nektar Therapeutics position peaked at $1.22M in Q1 2018.
  • 180 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.